Kyntra Bio, Inc.
KYNB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$4.50
KIRA · Stoqly’s AI analyst, in plain words
- Kyntra Bio, Inc. had $6.4M of revenue in fiscal 2025, down 78.3% on the year before. Over five years, revenue changed −48.4% a year on average.
- Its operating margin was −712.7%, down 204.9 pts: of every 100 in sales, about −713 is left after running the business.
- Kyntra Bio, Inc. made $183M of net profit in fiscal 2025.
- Free cash flow was −$4.8M in fiscal 2025, −74.7% of revenue.
Market cap
$18.2M
P/E
0.1x
Revenue
$6.4M
Net income
$183M
Free cash flow
−$4.8M
Operating margin
−712.7%
Kyntra Bio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−78.3%
No. Sales fell 78.3% last year.
Does it make a profit?
2,848.6%
Yes. It keeps 2,848.6% of every sale as profit.
Does profit turn into cash?
−74.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
0.1x
One share costs 0.1 times its yearly profit per share.
What Kyntra Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- KYNTRA BIO, INC.
- CIK
- 0000921299
Kyntra Bio, Inc. · KYNB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $235M | $141M | $46.8M | $29.6M | $6.4M |
| Revenue growth | 33.5% | −40.2% | −66.7% | −36.7% | −78.3% |
| Gross margin | 94.5% | 85.6% | 91.5% | 47.5% | 91.4% |
| Operating margin | −122.6% | −213.9% | −689.5% | −507.8% | −712.7% |
| Net income | −$290M | −$294M | −$284M | −$47.6M | $183M |
| Net margin | −123.3% | −208.7% | −607.3% | −160.6% | 2,848.6% |
| Diluted EPS | −$3.14 | −$3.14 | −$2.92 | −$11.89 | $45.37 |
| Cash | |||||
| Cash from operations | −$82.2M | −$146M | −$315M | −$138M | −$4.8M |
| Capital expenditure | $5.2M | $3.7M | $2.5M | $0.3M | $0.0M |
| Free cash flow | −$87.4M | −$150M | −$318M | −$138M | −$4.8M |
| FCF margin | −37.2% | −106.4% | −678.5% | −466.8% | −74.7% |
| Share count change | 2.8% | 1.3% | 4.0% | −95.9% | 1.0% |
| Debt and strength | |||||
| Cash and short-term investments | $405M | $422M | $203M | $50.5M | $89.0M |
| Shareholders' equity | $209M | −$21.4M | −$204M | −$226M | −$30.0M |
| Current ratio | 2.1x | 1.8x | 1.5x | 1.5x | 3.4x |
| Interest coverage | −268.4x | −209.0x | −39.9x | −18.2x | −5.2x |
| Returns and quality | |||||
| Return on equity | −91.9% | −312.9% | — | — | — |
| Return on tangible equity | −138.7% | — | — | — | — |
| Piotroski F-score | 2 | 1 | 1 | 3 | 4 |
| Altman Z'' | −5.3 | −9.3 | −17.9 | −32.1 | −45.5 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kyntra Bio, Inc. · KYNB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.50 a share, the company is worth $18.2M: 0.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000921299). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.